As a medical student, I see every day how uncontrolled blood sugar quietly destroys organs. Most of my classmates file this away for exam day, while I’m glued to my CGM app because these sequelae are not hypotheticals for me.

A continuous glucose monitor (CGM) has been the backbone of my daily management since my type 1 diabetes (T1D) diagnosis five years ago. On July 1, 2026, my longtime sensor will be officially discontinued. The plan is to fully transition patients to a newer-generation device: smaller, more streamlined, with a longer wear time.

It’s crucial to remember, however, that “newer” does not necessarily mean “better for everyone.” I was eager to try the replacement sensor until it repeatedly showed glucose readings in the high 200s. Over two days, I took multiple correction doses for inaccurate highs. Only after cross-checking with manual fingersticks did I discover I was actually within normal range. I had been stacking insulin against a potential phantom high, putting myself at real risk of hypoglycemia. It was then that I realized a bulkier sensor was a small price to pay for reliable readings.

My experience is not unique; it is a symptom of a growing trust gap within the T1D community. Many try the newer sensor, then switch right back to the legacy one. Online forums aren’t buzzing with excitement for the upgrade; they’re full of people worried about losing the device they rely on.

To be fair, the newer sensor offers true advantages: a faster warm-up, added grace periods, a 15-day lifespan, and broader pump integration. Yet it has faced FDA recalls, including a Class I in 2025 for failed receiver alerts, and a Class II as recent as April 14, 2026, for delayed sensor readings. No CGM is flawless, though, as the legacy sensor has had its share of similar recalls as well.

But let’s be real, most patients aren’t hunting for perfection; they just want something they can count on.

We can’t treat medical devices like consumer electronics. A new, laggy smartphone is annoying, while a CGM with documented inaccuracies and a 26.1 percent premature failure rate jeopardizes patient safety and confidence.

Some argue that patients unhappy with one CGM can easily switch to a competing system. In reality, it’s rarely that simple. Changing CGM systems often involves insurance headaches, a learning curve with a new app, and the loss of years of trend data that inform both patient and clinician decision-making.

For a patient population already managing 24/7 disease, this burden of switching platforms is not just a minor inconvenience.

It feels backwards: we are asking T1D patients to verify their CGM with the very fingersticks it was designed to replace. Many patients have stopped carrying backup supplies everywhere they go. Wasn’t the entire value proposition of CGMs freedom from the prick routine? When a sensor reads 50 mg/dL and the patient feels fine, someone without a glucometer has two choices: believe the device and correct it, or ignore it and hope for the best.

Both are gambles.

The replacement sensor isn’t new anymore; it’s been on the market for several years. So if patients stay hesitant, maybe we need to rethink what we call “success.” Is it solely about technological upgrades, or whether people actually feel comfortable and safe?

The best treatment plan is one that patients believe in and will follow. This principle should apply to medical devices. Transition timelines need to be driven by real-world safety benchmarks and patient-reported outcomes, not arbitrary boardroom deadlines. Regulatory requirements must ensure that no life-sustaining legacy device is discontinued until its successor has demonstrated sustained safety for at least 24 months of active market use.

Innovation counts only when it preserves patient safety and confidence. As the legacy sensor’s end-of-life nears, the real question is simple: Has every stable patient been given a supported path forward?

Arya Patel is a medical student.